Arcutis Biotherapeutics, Inc. (ARQT) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-05
(Q2 2026)
— full calendar
Earnings Reports
-
Arcutis (ARQT) Q1 2026: Zareve Captures 48% Branded Topical Share, Expanding Pediatric Reach
May 07, 2026
-
Arcutis (ARQT) Q4 2025: Zareve Captures 45% Segment Share as Non-Steroidal Topicals Displace Steroids
February 26, 2026
-
Arcutis (ARQT) Q3 2025: Zareve Net Revenue Jumps 122% as Steroid Conversion Accelerates
October 28, 2025
-
Arcutis (ARQT) Q2 2025: Zureve Franchise Drives 164% Revenue Surge as Steroid Conversion Accelerates
August 06, 2025
-
Arcutis (ARQT) Q1 2025: Zareve Scripts Jump 10% Despite Seasonal Headwinds, Underscoring Market Conversion Momentum
July 06, 2025
-
Arcutis (ARQT) Q3 2024: Zareev Sales Surge 452% as Non-Steroidal Topical Adoption Accelerates
November 06, 2024
-
Arcutis Biotherapeutics (ARQT) Q2 2024: Zareve Scripts Jump 42% as Indications Expand, Primary Care Push Builds for 2025
August 14, 2024
-
Arcutis (ARQT) Q1 2024: Zoryve Foam Drives 59% Sequential Revenue Jump as Portfolio Expansion Accelerates
May 14, 2024
-
Arcutis (ARQT) Q4 2023: Zoryve Foam Launch Drives 67% Sequential Revenue Growth, Expanding Addressable Market
February 27, 2024